Vaxcyte (PCVX) EBITDA (2019 - 2026)
Vaxcyte (PCVX) reported EBITDA of -$329.0 million for Q1 2026, down 139.88% year-over-year from $825.0 million in Q1 2025, and down 33.88% quarter-over-quarter from -$245.8 million in Q4 2025.
Vaxcyte (PCVX) EBITDA (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 8 years of EBITDA data on file, last reported at -$329.0 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$329.0 million, down 139.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$953.0 million (down 85.84% YoY), and the FY2025 annual result was -$761.2 million, down 62.65% from the prior year.
- EBITDA fell to -$329.0 million in Q1 2026 per PCVX's latest filing, from -$245.8 million in the prior quarter.
- Over five years, EBITDA peaked at -$39.6 million in Q1 2022 and troughed at -$329.0 million in Q1 2026.
- A 5-year average of -$129.0 million and a median of -$104.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2024: EBITDA plunged 190.07% in 2022, then grew 20.88% in 2024.
- A 5-year view of EBITDA shows it stood at -$86.6 million in 2022, then plunged by 105.99% to -$178.3 million in 2023, then gained by 20.88% to -$141.1 million in 2024, then plunged by 74.2% to -$245.8 million in 2025, then slumped by 33.88% to -$329.0 million in 2026.
- Business Quant data shows PCVX's EBITDA at -$329.0 million in Q1 2026, -$245.8 million in Q4 2025, and -$210.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -65.83 Mn |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - | -329.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -329.04 Mn |
| Dec 31, 2025 | -245.78 Mn |
| Sep 30, 2025 | -210.09 Mn |
| Jun 30, 2025 | -168.14 Mn |
| Mar 31, 2025 | -137.17 Mn |
| Dec 31, 2024 | -141.09 Mn |
| Sep 30, 2024 | -104.80 Mn |
| Jun 30, 2024 | -129.78 Mn |
| Mar 31, 2024 | -92.31 Mn |
| Dec 31, 2023 | -178.33 Mn |
| Sep 30, 2023 | -92.43 Mn |
| Jun 30, 2023 | -70.91 Mn |
| Mar 31, 2023 | -60.05 Mn |
| Dec 31, 2022 | -86.57 Mn |
| Sep 30, 2022 | -58.58 Mn |
| Jun 30, 2022 | -47.89 Mn |
| Mar 31, 2022 | -39.58 Mn |
| Dec 31, 2021 | -29.85 Mn |
| Sep 30, 2021 | -26.95 Mn |
| Jun 30, 2021 | -23.73 Mn |